X-rays show that patients with osteoarthritis who receive a hip steroid/anesthetic injection may develop osteonecrosis of the hip.
X-rays show that patients with osteoarthritis who receive steroid injections in the hip have a greater incidence of osteonecrosis, according to a study presented at RSNA.
Researchers from the United States evaluated the incidence of osteoarthritis progression, femoral head osteonecrosis, and articular surface collapse in patients with osteoarthritis who underwent hip steroid/anesthetic injections.
A total of 102 patients, aged 19 to 92, participated in the study; 62 were women. All underwent X-ray images of the treated hip at the time of the injection and during a follow-up three to nine months later; 123 hip steroid/anesthetic (40 mg triamcinolone, 4 mL 0.5% preservative free ropivicaine) injections were performed. Two musculoskeletal radiologists performed retrospective, blinded reviews of the pre- and post-injection radiography of hip injection patients (HIPs) and 2 demographic and follow-up duration matched control groups:
• Patients undergoing hip x-rays without injection
• Glenohumeral joint injection patients
The results showed new osteonecrosis in 22% to 24% HIPs, compared to 5% to 9% in the hip control group and 5% in the glenohumeral joint injection control group. Bone collapse was observed in the head of the femur in 15% to 17% of hip injection patients, versus 4% of hip control patients and 2% of glenohumeral joint injection control patients.
"Changes due to osteoarthritis, such as narrowing in the space between joints and the development of bony proliferations, typically develop slowly over time," co-author Connie Y. Chang, MD, a radiologist at Massachusetts General Hospital and assistant professor of radiology at Harvard Medical School in Boston, said in a release. "When reading follow-up radiographs of patients who had received a hip injection, we noticed changes had developed rapidly in some patients."
"We need to look at what's going on with the steroid/anesthetic injectate and osteoarthritis patients to determine what's causing the changes that occur in some patients," Chang continued. "However, we don't want to deter patients from getting an injection. These results are enough to warrant an investigation, but not enough to cancel a procedure."
[[{"type":"media","view_mode":"media_crop","fid":"64660","attributes":{"alt":"","class":"media-image","id":"media_crop_5192836293653","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"8276","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" 58-year-old woman with left hip pain. X-ray from one month prior to the steroid/anesthetic injection demonstrates moderate joint space narrowing (arrows) and bony proliferation (arrowheads). ©RSNA 2017","typeof":"foaf:Image"}}]]
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.